

# PreveCeutical Medical Inc.

14:54 20 Nov 2018

## PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

PreveCeutical Medical Inc (CSE:PREV, OTCMKTS:PRVCF) said Tuesday it has developed a way to convert phytocannabinoids extracted from the company's five cannabis strains from acid to neutral.

The Vancouver-based company said in a press release that it has confirmed the conversion of cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) to the neutral cannabidiol (CBD) and tetrahydrocannabinol (THC). It added that no degradation was detected.

**HEAD: PreveCeutical encouraged by gel spray nasal delivery of cannabis-based treatments**

"Having optimized the conditions for comprehensive conversion of phytocannabinoids from acid to neutral forms opens the door to a wider product range for Preveceutical," the company's chief research officer, Dr. Harendra Parekh, said in a statement.

PreveCeutical added that it has added five neutral cannabinoid extracts to its five acid cannabinoid extracts. The company plans to incorporate acid and neutral extracts into its soluble-gel drug delivery program.


On Monday, the company said it was encouraged by tests of nasal gel sprays to administer medical-based cannabis treatments of epilepsy, anxiety and depression.

Contact Dennis Fitzgerald at [dennis@proactiveinvestors.com](mailto:dennis@proactiveinvestors.com)

**Price:** 0.02

**Market Cap:** \$7.93 m

### 1 Year Share Price Graph



April 2019 September 2019 March 2020

### Share Information

**Code:** PREV

**Listing:** CSE

**52 week High Low**  
0.075 0.01

**Sector:** Medical technology & services

**Website:** [preveceutical.com](http://preveceutical.com)

### Company Synopsis:

*PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related

products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).